Endocyte Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
123,281.10
125,069.70
173,600.50
138,207.40
97,471.40
Total Accounts Receivable
6,353.20
706.40
8.70
55.10
273.00
Other Current Assets
3,697.30
1,262.30
1,266.40
993.20
728.30
Total Current Assets
133,331.50
127,038.30
174,875.60
139,255.70
98,472.80
Net Property, Plant & Equipment
3,839.40
3,970.70
3,398.40
3,205.10
2,182.40
Total Investments and Advances
25,571.70
81,761.20
-
-
-
Other Assets
115.00
31.20
111.60
1,033.60
107.10
Total Assets
162,857.60
212,801.40
178,385.60
143,494.40
100,762.30
Accounts Payable
5,435.50
1,234.80
1,262.60
1,381.50
376.40
Other Current Liabilities
68,228.00
5,650.20
4,926.40
4,180.60
4,169.80
Total Current Liabilities
73,663.50
6,885.00
6,189.00
5,562.20
4,546.20
Other Liabilities
965.40
912.30
850.50
784.80
731.90
Total Liabilities
74,628.90
7,797.30
7,039.40
6,347.00
5,278.10
Common Equity (Total)
88,228.70
205,004.10
171,346.10
137,147.40
95,484.10
Total Shareholders' Equity
88,228.70
205,004.10
171,346.10
137,147.40
95,484.10
Total Equity
88,228.70
205,004.10
171,346.10
137,147.40
95,484.10
Liabilities & Shareholders' Equity
162,857.60
212,801.40
178,385.60
143,494.40
100,762.30

About Endocyte

View Profile
Address
3000 Kent Avenue
West Lafayette Indiana 47906
United States
Employees -
Website http://www.endocyte.com
Updated 09/14/2018
Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells.